In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Leukemia
; 38(2): 412-415, 2024 02.
Article
in En
| MEDLINE
| ID: mdl-38155246
Full text:
1
Database:
MEDLINE
Main subject:
Pyrazoles
/
Niacinamide
Limits:
Humans
Language:
En
Journal:
Leukemia
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2024
Type:
Article